NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
No Result
View All Result
Home ALL Healthcare

Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children

by Emma Jones
June 28, 2021
A A
  • The authorisation enables emergency use of Actemra/RoActemra for the treatment of COVID-19 in hospitalised adult and paediatric patients

Basel, 25 June 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra/RoActemra® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and paediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The EUA is based on results from four randomised, controlled studies that evaluated Actemra/RoActemra for the treatment of COVID-19 in more than 5,500 hospitalised patients. The results of these studies suggest that Actemra/RoActemra may improve outcomes in patients receiving corticosteroids and requiring supplemental oxygen or breathing support.

“Even with the availability of vaccines and declines in deaths from COVID-19 in various parts of the world, we continue to see new hospitalisations from severe forms of the disease,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We are pleased that Actemra/RoActemra is now authorised as an option that may help improve outcomes for adults and children hospitalised with COVID-19 in the United States.”

The four randomised, controlled studies included in the EUA submission investigated the safety and efficacy of Actemra/RoActemra in more than 5,500 hospitalised patients with COVID-19. The RECOVERY Actemra/RoActemra study was led by researchers in the United Kingdom and included more than 4,000 hospitalised COVID-19 patients. Roche-sponsored global trials included the placebo-controlled EMPACTA, COVACTA and REMDACTA studies. There have been no new safety signals identified for Actemra/RoActemra in any of these studies. The most common adverse reactions seen (incidence ≥ 3%) are constipation, anxiety, diarrhoea, insomnia, hypertension and nausea.

The U.S. FDA Letter of Authorisation and Fact Sheets for patients and health care professionals are available for download with the latest information on this EUA. For more information on how Roche is responding to the global COVID-19 pandemic, please visit our COVID-19 response page.

In these exceptional times, Roche stands together with society, governments, healthcare providers and all those working to overcome the pandemic.

Tags: < Market
ShareTweetShareSend

Related Industries

Healthcare

Bayer Announces Changes to U.S. Country Leadership Team

June 9, 2023
Healthcare

Cardinal Health announces the merger of its Outcomes™ business into Transaction Data Systems and related partnership

June 6, 2023
Healthcare

Medtronic names Ken Washington new Chief Technology and Innovation Officer

June 2, 2023
Healthcare

BD Names Laura Boros President of Pharmaceutical Systems

June 2, 2023
Healthcare

Medtronic to acquire wearable insulin patch maker EOFlow

May 26, 2023
Healthcare

Thermo Fisher Scientific Releases 2022 Corporate Social Responsibility Report

May 18, 2023

Jolyon Bulley to become Americas CEO following Elie Maalouf’s appointment to Group CEO

May 18, 2023

...

Blackstone Acquires International Gemological Institute (IGI)

May 22, 2023

...

IonicBlue® receives up to CAD $100 million investment from Canada Infrastructure Bank toward decarbonization projects

May 24, 2023

...

3M and Svante announce joint development agreement to develop and produce carbon dioxide removal products

May 17, 2023

...

GE Hitachi Announces Intent to Transfer Ownership of Vallecitos Nuclear Center

May 10, 2023

...

GE Announces Chief Financial Officer Transition; Names Rahul Ghai Chief Financial Officer

May 19, 2023

...

GM Furthers Flint Commitment with $1B+ Manufacturing Investment

June 6, 2023

...

Intel and SAP Embark on Strategic Collaboration to Expand Cloud Capabilities

May 18, 2023

...

Alstom and EDC enter into a strategic partnership for sustainable mobility financing

May 17, 2023

...

NORTH AMERICAN BUSINESS (www.na-biz.com) is a leading source of business and corporate news, information, industry trends, market updates and insights across a broad spectrum of industries in North America and worldwide.

MENU

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor#na-biz.com

PARTNERSHIP:     biz#na-biz.com

HUMAN RESOURCE:     hr#na-biz.com

* (replace # with @)

  • Official Site

Copyright © NA-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © NA-BIZ.COM All rights reserved.